Biological barriers impede the application of bio-macromolecule based drugs in the clinics [1]. Small interfering RNA (siRNA) based drugs can be delivered to cells via endocytosis to silence the expression of disease causing genes [1, 2]. A major bottleneck in delivery, however, is the escape of siRNAs from endosomes to cytosol,
…